Analysis of antibiotic resistant infections associated with hirudotherapy
Brauer PR, Saadah M, Fritz MA, Wu SS, Lamarre ED (2024) · American Journal of Otolaryngology · n=19
Характеристика исследования
- Дизайн
- retrospective cohort analysis of all hirudotherapy-related adverse events (FDA product code NRN) reported to the FDA MAUDE database from 2012-2021 (Cleveland Clinic Head and Neck Institute + Case Western Reserve, USA)
- Размер выборки (n)
- 19
- Вмешательство
- Whole-leech medicinal leech therapy in patients reported to MAUDE for adverse events involving antibiotic resistance (any organism, any clinical setting)
- Компаратор
- Not applicable — descriptive cohort with no comparator arm
- Первичная конечная точка
- Incidence and microbiology of antibiotic-resistant infections after hirudotherapy
- Основной результат
- 19 cases of antibiotic-resistant hirudotherapy infections identified; 16/19 (84.2%) associated with patient injury; positive cultures or fever in 26.3%; Aeromonas hydrophila most common (13/19, 68.4%), followed by Vibrio vulnificus (3/19), Pseudomonas aeruginosa (2/19), Proteus vulgaris (1/19); 9/19 (47.4%) multi-drug resistant; resistance documented to fluoroquinolones (47.4%), TMP-SMX (47.4%), and ertapenem (21.1% — a drug of last resort)
- Длительность наблюдения
- 10-year MAUDE reporting window (2012-2021)
- PMID
- 39208707
Ключевые выводы
- 19 MAUDE reports of antibiotic-resistant infections after hirudotherapy (2012-2021)
- Aeromonas hydrophila accounts for 68.4% — consistent with the established leech-gut symbiont profile
- Vibrio vulnificus (15.8%) emerges as a new concern requiring different prophylactic coverage than ciprofloxacin
- 47.4% multi-drug resistance and 21.1% ertapenem resistance represent escalating stewardship pressure
- Findings support shift toward culture-directed therapy and avoidance of empiric fluoroquinolone monotherapy
Ограничения
- MAUDE is a voluntary passive surveillance database — significant underreporting likely
- No denominator data (total hirudotherapy procedures performed) — cannot estimate incidence
- No standardized infection definitions across reports
- Some reports lacked complete antibiogram data
- Single-decade window may miss emerging-resistance trends from earlier hirudotherapy
Клиническое значение
Brauer 2024 is now the largest US dataset documenting antibiotic-resistant infection trends in hirudotherapy and directly informs ASH stewardship guidance. For US clinicians using leech therapy under K040187, the data argue for (1) culture-directed antibiotic selection rather than reflexive ciprofloxacin monotherapy, (2) coverage that anticipates Vibrio vulnificus in maritime exposure or coastal patient populations, and (3) early infectious-disease consultation when MDR organisms are isolated. The findings also support continued investment in pharmacologic-leeching alternatives (Harun 2018 bivalirudin) for patients at high MDR risk.
Связанные исследования
Medicinal leech therapy in venous congestion of microsurgical flaps: a randomized comparison with heparin pinprick scarification
Merlino G, Carbone S, Servillo G, Marletta DA (2020)
Adjunctive medicinal leech therapy for venous congestion in free flaps: a German multicenter randomized trial
Lehnhardt M, Daigeler A, Behr B, Schmidt SV, Wallner C (2021)
Medicinal leeches and the microsurgeon: a four-year study, clinical series and risk benefit review
Whitaker IS, Josty IC, Hawkins S, Azzopardi E, Naderi N, Graf J, Damaris L, Lineaweaver WC, Kon M (2011)
Medicinal leeches for surgically uncorrectable venous congestion after free flap breast reconstruction
Pannucci CJ, Nelson JA, Chung CU, Fischer JP, Kanchwala SK, Kovach SJ, Serletti JM, Wu LC (2014)